08/05/22 3:00 PMNasdaq : PCSA conferenceslow floatProcessa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. ESTProcessa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host aRHEA-AIneutral
08/04/22 9:30 AMNasdaq : PCSA clinical triallow floatProcessa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announcesRHEA-AIneutral
08/03/22 4:00 PMNasdaq : PCSA clinical triallow floatProcessa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announcesRHEA-AIneutral
07/12/22 8:30 AMNasdaq : PCSA conferenceslow floatProcessa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions announced todayRHEA-AIvery positive
05/12/22 4:20 PMNasdaq : PCSA earningslow floatProcessa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate UpdateProcessa Pharmaceuticals, Inc. (Nasdaq:RHEA-AIneutral
05/05/22 8:30 AMNasdaq : PCSA conferenceslow floatProcessa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. ESTProcessa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host aRHEA-AIneutral
04/20/22 8:30 AMNasdaq : PCSA clinical triallow floatProcessa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)Processa f ocuse s on i dentify ing the PCS6422 regimens to i ncrease c apecitabine potency while identifying the MTD of Next Generation Capecitabine The amended p rotocol will provi de a more precise timeline of DPD inhibition and de novo formation while also supplying preliminary data on the us eRHEA-AIneutral
04/05/22 8:30 AMNasdaq : PCSA clinical triallow floatProcessa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of GastroparesisProcessa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or theRHEA-AIneutral
03/30/22 4:00 PMNasdaq : PCSA low floatProcessa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate UpdateProcessa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve aRHEA-AIneutral
03/23/22 8:30 AMNasdaq : PCSA conferenceslow floatProcessa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. ESTProcessa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host aRHEA-AIneutral